The Efficiency of Cyclosporine A-Eluting Contact Lenses for the Treatment of Dry Eye

References

• Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, Liu Z, Nelson JD, Nichols JJ, Tsubota K, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276–83. doi:10.1016/j.jtos.2017.05.008.
   PubMed Web of Science ®Google Scholar
• Sheppard JD. Guidelines for the treatment of chronic dry eye disease. Manag Care. 2003;12:20–25.
   PubMedGoogle Scholar
• Paulsen AJ, Cruickshanks KJ, Fischer ME, Huang GH, Klein BE, Klein R, Dalton DS. Dry eye in the beaver dam offspring study: prevalence, risk factors, and health-related quality of life. Am J Ophthalmol. 2014;157(4):799–806. doi:10.1016/j.ajo.2013.12.023.
   PubMed Web of Science ®Google Scholar
• Calonge M. The treatment of dry eye. Surv Ophthalmol. 2001;45:S227–239.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Aller M, Kaufmann B, Guillarme D, Stella C, Furrer P, Rudaz S, El Zaoui I, Valamanesh F, Di Tommaso C, Behar-Cohen F, et al. In vivo characterisation of a novel water-soluble Cyclosporine A prodrug for the treatment of dry eye disease. Eur J Pharm Biopharm. 2012;80(3):544–52. doi:10.1016/j.ejpb.2011.11.017.
   PubMed Web of Science ®Google Scholar
• Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol. 2012;130(1):90–100. doi:10.1001/archophthalmol.2011.364.
   PubMedGoogle Scholar
• Jiang D, Liu X, Hu J. Topical administration of Esculetin as a potential therapy for experimental dry eye syndrome. Eye (Lond). 2017;31(12):1724–32. doi:10.1038/eye.2017.117.
   PubMed Web of Science ®Google Scholar
• Utine CA, Stern M, Akpek EK. Clinical review: topical ophthalmic use of cyclosporin A. Ocul Immunol Inflamm. 2010;18(5):352–61. doi:10.3109/09273948.2010.498657.
   PubMed Web of Science ®Google Scholar
• Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 study group. Ophthalmology. 2000;107:631–39.
   PubMed Web of Science ®Google Scholar
• Gupta C, Chauhan A. Ophthalmic delivery of cyclosporine A by punctal plugs. J Control Release. 2011;150(1):70–76. doi:10.1016/j.jconrel.2010.11.009.
   PubMed Web of Science ®Google Scholar
• Lallemand F, Felt-Baeyens O, Besseghir K, Behar-Cohen F, Gurny R. Cyclosporine A delivery to the eye: a pharmaceutical challenge. Eur J Pharm Biopharm. 2003;56:307–18.
   PubMed Web of Science ®Google Scholar
• Maulvi FA, Choksi HH, Desai AR, Patel AS, Ranch KM, Vyas BA, Shah DO. pH triggered controlled drug delivery from contact lenses: addressing the challenges of drug leaching during sterilization and storage. Colloids Surf B Biointerfaces. 2017;157:72–82. doi:10.1016/j.colsurfb.2017.05.064.
   PubMed Web of Science ®Google Scholar
• Maulvi FA, Desai AR, Choksi HH, Patil RJ, Ranch KM, Vyas BA, Shah DO. Effect of surfactant chain length on drug release kinetics from microemulsion-laden contact lenses. Int J Pharm. 2017;524(1–2):193–204. doi:10.1016/j.ijpharm.2017.03.083.
   PubMed Web of Science ®Google Scholar
• Peterson RC, Wolffsohn JS, Nick J, Winterton L, Lally J. Clinical performance of daily disposable soft contact lenses using sustained release technology. Cont Lens Anterior Eye. 2006;29(3):127–34. doi:10.1016/j.clae.2006.03.004.
   PubMedGoogle Scholar
• Wolffsohn JS, Hunt OA, Chowdhury A. Objective clinical performance of “comfort-enhanced” daily disposable soft contact lenses. Cont Lens Anterior Eye. 2010;33(2):88–92. doi:10.1016/j.clae.2010.01.004.
   PubMed Web of Science ®Google Scholar
• Soluri A, Hui A, Jones L. Delivery of ketotifen fumarate by commercial contact lens materials. Optom Vis Sci. 2012;89(8):1140–49. doi:10.1097/OPX.0b013e3182639dc8.
   PubMed Web of Science ®Google Scholar
• Guzman-Aranguez A, Colligris B, Pintor J. Contact lenses: promising devices for ocular drug delivery. J Ocul Pharmacol Ther. 2013;29(2):189–99. doi:10.1089/jop.2012.0212.
   PubMed Web of Science ®Google Scholar
• Karn PR, Cho W, Park HJ, Park JS, Hwang SJ. Characterization and stability studies of a novel liposomal cyclosporin A prepared using the supercritical fluid method: comparison with the modified conventional Bangham method. Int J Nanomedicine. 2013;8:365–77. doi:10.2147/IJN.S39025.
   PubMed Web of Science ®Google Scholar
• Kim J, Conway A, Chauhan A. Extended delivery of ophthalmic drugs by silicone hydrogel contact lenses. Biomaterials. 2008;29(14):2259–69. doi:10.1016/j.biomaterials.2008.01.030.
   PubMed Web of Science ®Google Scholar
• Kakisu K, Matsunaga T, Kobayakawa S, Sato T, Tochikubo T. Development and efficacy of a drug-releasing soft contact lens. Invest Ophthalmol Vis Sci. 2013;54(4):2551–61. doi:10.1167/iovs.12-10614.
   PubMed Web of Science ®Google Scholar
• OECD guideline for the testing of chemicals. [ accessed 2018 April 11]. https://ntp.niehs.nih.gov/iccvam/suppdocs/feddocs/oecd/oecd-tg405-2012-508.pdf.
   Google Scholar
• Wilhelmus KR. The Draize eye test. Surv Ophthalmol. 2001;45:493–515.
   PubMed Web of Science ®Google Scholar
• Xiong C, Chen D, Liu J, Liu B, Li N, Zhou Y, Liang X, Ma P, Ye C, Ge J, et al. A rabbit dry eye model induced by topical medication of a preservative benzalkonium chloride. Invest Ophthalmol Vis Sci. 2008;49(5):1850–56. doi:10.1167/iovs.07-0720.
   PubMed Web of Science ®Google Scholar
• Bhattacharya D, Ning Y, Zhao F, Stevenson W, Chen R, Zhang J, Wang M. Tear production after bilateral main lacrimal gland resection in rabbits. Invest Ophthalmol Vis Sci. 2015;56(13):7774–83. doi:10.1167/iovs.15-17550.
   PubMed Web of Science ®Google Scholar
• Kang H, Cha KH, Cho W, Park J, Park HJ, Sun BK, Hyun SM, Hwang SJ. Cyclosporine Amicellar delivery system for dry eyes. Int J Nanomedicine. 2016;11:2921–33. doi:10.2147/IJN.S107569.
   PubMed Web of Science ®Google Scholar
• Gautheron PD, Lotti VJ, Le Douarec JC. Tear film breakup time prolonged with unmedicated cellulose polymer inserts. Arch Ophthalmol. 1979;97:1944–47.
   PubMedGoogle Scholar
• Pauly A, Brignole-Baudouin F, Labbé A, Liang H, Warnet J-M, Baudouin C. New tools for the evaluation of toxic ocular surface changes in the rat. Invest Ophthalmol Vis Sci. 2007;48(12):5473–83. doi:10.1167/iovs.06-0728.
   PubMed Web of Science ®Google Scholar
• Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol. 2002;120:330–37.
   PubMed Web of Science ®Google Scholar
• Dursun D, Wang M, Monroy D, Li DQ, Lokeshwar BL, Stern ME, Pflugfelder SC. A mouse model of keratoconjunctivitis sicca. Invest Ophthalmol Vis Sci. 2002;43:632–38.
   PubMed Web of Science ®Google Scholar
• Brown MM, Brown GC, Brown HC, Peet J, Roth Z. Value-based medicine, comparative effectiveness, and cost-effectiveness analysis of topical cyclosporine for the treatment of dry eye syndrome. Arch Ophthalmol. 2009;127(2):146–52. doi:10.1001/archophthalmol.2008.608.
   PubMedGoogle Scholar
• Pflugfelder SC. Integrating restasis into the management of dry eye. Int Ophthalmol Clin. 2006;46(4):101–03. doi:10.1097/01.iio.0000212137.85298.98.
   PubMedGoogle Scholar
• Novack GD. Ophthalmic drug delivery: development and regulatory considerations. Clin Pharmacol Ther. 2009;85(5):539–43. doi:10.1038/clpt.2008.297.
   PubMed Web of Science ®Google Scholar
• Kearns VR, Williams RL. Drug delivery systems for the eye. Expert Rev Med Devices. 2009;6(3):277–90. doi:10.1586/erd.09.4.
   PubMed Web of Science ®Google Scholar
• Sahoo SK, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov Today. 2008;13(3–4):144–51. doi:10.1016/j.drudis.2007.10.021.
   PubMed Web of Science ®Google Scholar
• Carvalho IM, Marques CS, Oliveira RS, Coelho PB, Costa PC, Ferreira DC. Sustained drug release by contact lenses for glaucoma treatment-a review. J Control Release. 2015;202:76–82. doi:10.1016/j.jconrel.2015.01.023.
   PubMed Web of Science ®Google Scholar
• Maulvi FA, Shaikh AA, Lakdawala DH, Desai AR, Pandya MM, Singhania SS, Vaidya RJ, Ranch KM, Vyas BA, Shah DO. Design and optimization of a novel implantation technology in contact lenses for the treatment of dry eye syndrome: in vitro and in vivo evaluation. Acta Biomater. 2017;53:211–21. doi:10.1016/j.actbio.2017.01.063.
   PubMed Web of Science ®Google Scholar
• Chandasana H, Prasad YD, Chhonker YS, Chaitanya TK, Mishra NN, Mitra K, Shukla PK, Bhatta RS. Corneal targeted nanoparticles for sustained natamycin delivery and their PK/PD indices: an approach to reduce dose and dosing frequency. Int J Pharm. 2014;477(1–2):317–25. doi:10.1016/j.ijpharm.2014.10.035.
   PubMed Web of Science ®Google Scholar
• Jung HJ, Abou-Jaoude M, Carbia BE, Plummer C, Chauhan A. Glaucoma therapy by extended release of timolol from nanoparticle loaded silicone-hydrogel contact lenses. J Control Release. 2013;165(1):82–89. doi:10.1016/j.jconrel.2012.10.010.
   PubMed Web of Science ®Google Scholar
• Gulsen D, Chauhan A. Ophthalmic drug delivery through contact lenses. Invest Ophthalmol Vis Sci. 2004;45:2342–47.
   PubMed Web of Science ®Google Scholar
• Hsu KH, Carbia BE, Plummer C, Chauhan A. Dual drug delivery from vitamin E loaded contact lenses for glaucoma therapy. Eur J Pharm Biopharm. 2015;94:312–21. doi:10.1016/j.ejpb.2015.06.001.
   PubMed Web of Science ®Google Scholar
• Maulvi FA, Soni TG, Shah DO. A review on therapeutic contact lenses for ocular drug delivery. Drug Deliv. 2016;23(8):3017–26. doi:10.3109/10717544.2016.1138342.
   PubMed Web of Science ®Google Scholar
• Maulvi FA, Mangukiya MA, Patel PA, Vaidya RJ, Koli AR, Ranch KM, Shah DO. Extended release of ketotifen from silica shell nanoparticle-laden hydrogel contact lenses: in vitro and in vivo evaluation. J Mater Sci Mater Med. 2016;27(6):113. doi:10.1007/s10856-016-5724-3.
   PubMed Web of Science ®Google Scholar
• Kim MS, Jin SJ, Kim JS, Park HJ, Song HS, Neubert RH, Hwang SJ. Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. Eur J Pharm Biopharm. 2008;69(2):454–65. doi:10.1016/j.ejpb.2008.01.007.
   PubMed Web of Science ®Google Scholar
• Kinoshita S, Kiorpes TC, Friend J, Thoft RA. Goblet cell density in ocular surface disease. A better indicator than tear mucin. Arch Ophthalmol. 1983;101:1284–87.
   PubMedGoogle Scholar
• Kim MS, Kim JS, Park HJ, Cho WK, Cha KH, Hwang S-J. Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process. Int J Nanomedicine. 2011;6:2997–3009. doi:10.2147/IJN.S26546.
   PubMed Web of Science ®Google Scholar